The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: An eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study

Clinical Therapeutics

Volumn 27, Issue 5, 2005, Pages 531-542

  Make, Barry ^a   Hanania, Nicola A ^b   ZuWallack, Richard ^c   Kalberg, Christopher ^d   Emmett, Amanda ^d   Brown, Christy P ^d   Knobil, Katharine ^d  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Albuterol; Anticholinergic; Chronic obstructive pulmonary disease (COPD); Fluticasone propionate; Inhaled corticosteroid; Ipratropium; Long acting beta2 agonist; Salmeterol

Indexed keywords

ADVAIR DISKUS; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALBUTAMOL; UNCLASSIFIED DRUG; VENTOLIN INHALATION AEROSOL;

ADULT; AGED; AREA UNDER THE CURVE; AROUSAL; ARTICLE; BREAST CANCER; CAUCASIAN; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEADACHE; HEART INFARCTION; HEMATEMESIS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; NIGHT; OSTEOMYELITIS; PEAK EXPIRATORY FLOW; PREDICTION; RACE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SCREENING; SEX RATIO; SLEEP; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; AREA UNDER CURVE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 20644444351     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.05.009     Document Type: Article

References (37)

1. for the GOLD Scientific Committee Pauwels RA, Buist AS, and Calverley PM Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary Am J Respir Crit Care Med 163 2001 1256 1276
2. for the ATS/ERS Task Force Celli BR, and MacNee W Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946
3. Whittaker AJ, and Spiro SG Inhaled steroid therapy in chronic obstructive pulmonary disease Curr Opin Pulm Med 6 2000 104 109
4. Auffarth B, Postma DS, and de Monchey JG Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease Thorax 46 1991 372 377
5. for the Dutch Chronic Non-specific Lung Disease Study Group Kerstjens HA, Brand PL, and Hughes MD A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease N Engl J Med 327 1992 1413 1419
6. Weiner P, Weiner M, Azgad Y, and Zamir D Inhaled budesonide therapy for patients with stable COPD Chest 108 1995 1568 1571
7. Thompson AB, Daughton D, and Robbins RA Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters Am Rev Respir Dis 140 1989 1527 1537
8. Dompeling E, van Schayck CP, and Molema J Inhaled beclomethasone improves the course of asthma and COPD Eur Respir J 5 1992 945 952
9. for the International COPD Study Group Paggiaro PL, Dahle R, and Bakran I Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease [published correction appears in Lancet. 1998;351:1968] Lancet 351 1998 773 780
10. Burge PS, Calverley PM, and Jones PW Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial BMJ 320 2000 1297 1303
11. Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl Med 343 2000 1902 1909
12. COMBIVENT Inhalation Aerosol Study Group In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial Chest 105 1994 1411 1419
13. Van Noord JA, de Munck DR, and Bantje TA Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium Eur Respir J 15 2000 878 885
14. ZuWallack RL, Mahler DA, and Reilly D Salmeterol plus theophylline combination therapy in the treatment of COPD Chest 119 2001 1661 1670
15. for the Trial of Inhaled Steroids and Long-Acting Beta2 Agonists Study Group Calverley P, Pauwels R, and Vestbo J Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial [published correction appears in Lancet. 2002;361:1660] Lancet 361 2003 449 456
16. Hanania NA, Darken P, and Horstman D The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD Chest 124 2003 834 843
17. Mahler DA, Wire P, and Horstman D Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease Am J Respir Crit Care Med 166 2002 1084 1091
18. [published correction appears in Eur Respir J. 2003;21:912] Szafranski W, Cukier A, and Ramirez A Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74 81
19. Calverley PM, Boonsawat W, and Cseke Z Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Eur Respir J 22 2003 912 919
20. Donohue J, Kalberg C, and Emmett A A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD Treat Respir Med 3 2004 173 181
21. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986 Am Rev Respir Dis 136 1987 225 244
22. Linder A Symptom scores as measures of the severity of rhinitis Clin Allergy 18 1988 29 37
23. Chapman CR, Casey KL, and Dubner R Pain measurement: An overview Pain 22 1985 1 31
24. American Thoracic Society Dyspnea. Mechanisms, assessment, and management: A consensus statement Am J Respir Crit Care Med 159 1999 321 340
25. Mahler DA, Weinberg DH, Wells CK, and Feinstein AR The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes Chest 85 1984 751 758
26. Witek TJ Jr, and Mahler DA Meaningful effect size and patterns of response of the transition dyspnea index J Clin Epidemiol 56 2003 248 255
27. Witek TJ Jr, and Mahler DA Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur Respir J 21 2003 267 272
28. Mak JC, Nishikawa M, and Barnes PJ Glucocorticosteroids increase β2-adrenergic receptor transcription in human lung Am J Physiol 12 1995 L41 L46
29. 2-adrenergic receptor function in human nasal mucosa Am J Respir Crit Care Med 155 1997 704 710
30. Pang L, and Knox AJ Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth muscle cells Am J Respir Cell Mol Biol 23 2000 79 85
31. Mahler DA, Donohue JF, and Barbee RA Efficacy of salmeterol xinafoate in the treatment of COPD Chest 115 1999 957 965
32. Renard SI, Anderson W, and ZuWallack R Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1087 1092
33. Donohue JF, van Noord JA, and Bateman ED A 6-month, placebo-controlled study comparing lung function and healthy status changes in COPD patients treated with tiotropium or salmeterol Chest 122 2002 47 55
34. for the Dutch/Belgian Tiotropium Study Group Vincken W, van Noord JA, and Greefhorst AP Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Eur Respir J 19 2002 209 216
35. [published correction appears in Thorax. 2005;60:105] Brusasco V, Hodder R, and Miravitlles M Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax 58 2003 399 404
36. Wolkove N, Dajczman E, Colacone A, and Kreisman H The relationship between pulmonary function and dyspnea in obstructive lung disease Chest 96 1989 1247 1251
37. O'Donnell DE, Lam M, and Webb KA Spirometric correlates of improvement in exercise performance after anti-cholinergic therapy in chronic obstructive pulmonary disease Am J Respir Crit Care Med 160 1999 524 549